Filing Flows › Keros Therapeutics (KROS) › Q4 2025
Keros Therapeutics (KROS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 4, 2026
Keros Therapeutics (KROS) reported revenue of $380K for the fourth quarter 2025 (Q4 2025), -88% from a year earlier and -97% from the quarter before.
Keros Therapeutics, Q4 2025: revenue $380K (-88% year over year), net loss $23.5M, operating cash flow −$27.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $380K | -97% | -88% |
| Operating profit | −$29.3M | — | — |
| Net earnings | −$23.5M | — | — |
| Operating cash flow | −$27.3M | -940% | — |
What changed
Revenue was $380K in Q4 2025, down 88% year over year and down 97% from the previous quarter.
Operating costs exceeded revenue by $29.3M, an operating margin of -7702.6%. Total costs fell 47% while revenue fell 88%. The fastest-growing cost line was General & admin (+10%). The quarter ended with a net loss of $23.5M, wider than the previous quarter's $7.3M loss.
Operating cash flow was −$27.3M. Non-cash charges added back $400K of depreciation and $7.3M of share-based compensation. Working capital and other items used $11.5M. Capital expenditures of $134K exceeded it, leaving free cash flow of −$27.4M.
Questions
What was Keros Therapeutics' revenue in the fourth quarter 2025?
Keros Therapeutics (KROS) reported revenue of $380K for the fourth quarter 2025 (Q4 2025), -88% from a year earlier and -97% from the quarter before.
Source: Keros Therapeutics 10-K on SEC EDGAR.